Transgenic expression of ALOX15 suppresses TNF-α and iNOS expression as well as NF-κB activation and downregulates LRP5 to suppress Wnt/β-catenin signaling, thereby inhibiting colon cancer [79,80]. Here, LRP5 is linked to malignant colon neoplasm.